Zelminemab

Names

[ CAS No. ]:
2225850-33-7

[ Name ]:
Zelminemab

Biological Activity

[Description]:

Zelminemab (AMG-301) is a human monoclonal antibody that inhibits PACAP type I (PAC1) receptor[1].

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> Adenylate Cyclase

Research Areas >> Neurological Disease

[In Vivo]

Zelminemab（10 mg/kg；i.v.；一次）降低 TCC 中的伤害性神经元活动[2]。 Animal Model: Sprague-Dawley rats, electricalstimulation was performed on the intact dura mater abovethe middle meningeal artery[2]. Dosage: 10 mg/kg Administration: i.v.; once Result: Induced an inhibition of stimulus-evoked nociceptive activity in the trigeminocervical com-plex (TCC).

[References]

[1]. Eloisa Rubio-Beltrán, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018 Aug 7;19(1):64.

[2]. Hoffmann J, et al. PAC-1 receptor antibody modulates nociceptive trigeminal activity in rat. Cephalalgia. 2016;36(1S):141–141.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.